News Center

Home page

Peak Report

News reports

Jianfeng Group Lin2016 -028 (Announcement on Acceptance Notice of Drug Clinical Trial Application of Subsidiary Company)

Release time:

2020-08-05

Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2016-028

Bond Abbreviation: 13 Peak 01 Bond Code: 122227

Bond Abbreviation: 13 Peak 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Announcement on Acceptance Notice of Subsidiary Drug Clinical Trial Application

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

1. Summary

Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a controlling subsidiary of the Company, received the Notice of Acceptance of Drug Registration Application (Acceptance No.: CXHL1600201 Zhejiang) and (Acceptance No.: CXHL1600202 Zhejiang) issued by Zhejiang Food and Drug Administration. The clinical research application of deoxypodophyllotoxin for injection (acceptance number: CXHL1600202 Zhejiang) and its bulk drug (acceptance number: CXHL1600201 Zhejiang) (hereinafter collectively referred to as "DPT") developed by Jianfeng Pharmaceutical and China Pharmaceutical University has been accepted by Zhejiang Food and Drug Administration.

2. drug basic information content

(I) deoxypodophyllotoxin

drug name: deoxypodophyllotoxin

dosage form: non-preparation: bulk drug

packing specification: 2Kg

per bag application item: chemical drug: class 1

Application Stage: Clinical

Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd., China Pharmaceutical University

Application Acceptance Number: CXHL1600201 Zhejiang

Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.

(II) Deoxypodophyllotoxin for Injection

Drug Name: Deoxypodophyllotoxin for Injection

Dosage Form: Preparation: Chinese Pharmacopoeia Dosage Form Injection

Specification: 100mg Package Specification: 1 bottle per box

Application Item: Chemical Drug: 1 Class

Application Stage: clinical

Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd. and China Pharmaceutical University

Application Acceptance Number: CXHL1600202 Zhejiang

3. Drug Research and Development and Registration

DPT Project is a new anti-tumor drug developed by Jianfeng Pharmaceutical in cooperation with China Pharmaceutical University in March 112. Domestic and foreign listed alkaloids of similar drugs include: paclitaxel, vinorelbine. DPT indication/ function indication is tentatively designated as first-line and second-line treatment of lung cancer, breast cancer and gastric cancer; Especially for the treatment of the above tumors resistant to paclitaxel and vinorelbine.

DPT is currently in the stage of applying for clinical trial approval. After the clinical application of is accepted, the clinical research work can only be carried out after passing the review and approval of the State Food and Drug Administration (CFDA) and obtaining the clinical trial approval document. After the clinical trial is completed, the production can be applied, after passing the review and approval of CFDA and obtaining the drug production approval, can be produced and marketed.

Up to now, the accumulated research and development investment and other related expenditures of DPT project of Jianfeng Pharmaceutical Co., Ltd. are about 33 million yuan. The impact of

4. on listed companies and risk tips

DPT clinical application filed by the company has been accepted and will not have a significant impact on the company's recent operating results. After the clinical application of

is accepted, the clinical research work can only be carried out after passing the review and approval of CFDA and obtaining the clinical trial approval document. The results and time of the inspection, review and approval during the period are uncertain. Due to the long cycle and high risk of new drug research and development, the company will timely fulfill the obligation of information disclosure according to the progress of research and development. Please pay attention to the investment risk.

hereby announce

Zhejiang Jianfeng Group Co., Ltd. Board of Directors

August 25, 2016

More information

Representatives of the 20th Congress preached the 20th Congress at the peak.

On the afternoon of November 11, a special lecture on the spirit of the Party's 20th Congress was held in the conference room of the Peak Building. Yang Xiayun, a representative of the 20th National Congress, walked into the peak and preached his understanding of the spirit of the 20th National Congress for Party members through personal experience.

2022

11-23

The group party committee organizes and learns the twenty spirits.

On the afternoon of October 28, the party Committee of the group organized all members to hold a special study meeting to earnestly study and understand the communique of the first plenary session of the 20th central Committee of the communist party of China and the revision of the party constitution. Jiang Xiaomeng, Secretary of the Party committee of the group, stressed at the study meeting that the 20th National Congress of the Communist Party of China has drawn a grand blueprint for building a socialist modern country in an all-round way, opened a new chapter in the era of national development, and pointed out the direction for the future development of enterprises. Party organizations at all levels of the group should pay full attention to and earnestly implement it, actively organize party members and cadres to learn the spirit of the spirit of the 20th National Congress, And to guide the future work practice.

2022

11-01

Spike Party Members and Cadres Watch the Opening Meeting of the 20th Congress

At 10 a.m. on October 16, the 20th National Congress of the Communist Party of China was solemnly opened in the Great Hall of the People in Beijing. Xi Jinping delivered a report to the Party's 20th National Congress on behalf of the 19th Central Committee. The group company attaches great importance to and carefully deploys, and organizes all party members and management backbones of the group headquarters and subsidiaries to watch the live broadcast of the opening meeting through the Internet, TV and other methods.

2022

10-23

Provincial torchbearers, there are two spikes!

2022

10-08

Jiang Xiaomeng was hired as the "Shuanglong Escort" entrepreneurial mentor.

On September 16, Jiang Xiaomeng, Secretary of the Party committee and chairman of the group company, was employed as the entrepreneurial mentor of "Shuanglong escort" at the launching ceremony of the special action of "Shuanglong escort steady progress and quality improvement" held in Jinhua City and the promotion meeting of innovative products of key talent enterprises in Jinhua City.

2022

09-27

The 12th Congress of Zhejiang Federation of Industry and Commerce Held in Hangzhou Chairman Jiang Xiaomeng Re-elected Vice President of Provincial Chamber of Commerce

From August 18th to 19th, the 12th Congress of the Zhejiang Federation of Industry and Commerce was held in Hangzhou, and the 12th leadership of the Provincial Federation of Industry and Commerce was elected. Jiang Xiaomeng, Secretary of the Party Committee and Chairman of the Group, was re-elected as Vice President of Zhejiang Chamber of Commerce.

2022

09-01

< 1...3 4 5...61 > 跳转到页